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PURPOSE. We characterize calpain-5 (CAPN5) expression in retinal and neuronal subcellular
compartments.
METHODS. CAPN5 gene variants were classified using the exome variant server, and RNA-
sequencing was used to compare expression of CAPN5 mRNA in the mouse and human retina
and in retinoblastoma cells. Expression of CAPN5 protein was ascertained in humans and
mice in silico, in mouse retina by immunohistochemistry, and in neuronal cancer cell lines
and fractionated central nervous system tissue extracts by Western analysis with eight
antibodies targeting different CAPN5 regions.
RESULTS. Most CAPN5 genetic variation occurs outside its protease core; and searches of
cancer and epilepsy/autism genetic databases found no variants similar to hyperactivating
retinal disease alleles. The mouse retina expressed one transcript for CAPN5 plus those of
nine other calpains, similar to the human retina. In Y79 retinoblastoma cells, the level of
CAPN5 transcript was very low. Immunohistochemistry detected CAPN5 expression in the
inner and outer nuclear layers and at synapses in the outer plexiform layer. Western analysis of
fractionated retinal extracts confirmed CAPN5 synapse localization. Western blots of
fractionated brain neuronal extracts revealed distinct subcellular patterns and the potential
presence of autoproteolytic CAPN5 domains.
CONCLUSIONS. CAPN5 is moderately expressed in the retina and, despite higher expression in
other tissues, hyperactive disease mutants of CAPN5 only manifest as eye disease. At the
cellular level, CAPN5 is expressed in several different functional compartments. CAPN5
localization at the photoreceptor synapse and with mitochondria explains the neural circuitry
phenotype in human CAPN5 disease alleles.
Keywords: CAPN5, calpain, autosomal dominant neovascular inflammatory vitreoretinopathy,
ADNIV
Mutation of the calcium-activated protease calpain-5(CAPN5) can cause a severe blinding disease, autosomal
dominant neovascular inflammatory vitreoretinopathy (ADNIV,
OMIM #193235).1–5 In their twenties, ADNIV patients begin to
display a synaptic signaling defect and intraocular inflammation
(uveitis). Over the ensuing five decades, they experience retinal
degeneration, retinal neovascularization, and intraocular fibro-
sis, culminating in phthisis and blindness.1–3 Although CAPN5
is expressed in many tissues, ADNIV patients only manifest
disease in the eye.6 Autosomal dominant neovascular inflam-
matory vitreoretinopathy CAPN5 is hyperactive, since the
disease allele reduces the calcium level required for protease
activity.7 Thus, the eye-restricted phenotype likely reflects the
extraordinarily high calcium concentrations in the retina,
where such a hyperactive calcium-dependent protease could
be particularly damaging.3,5
Increased calpain activity is a feature of many eye-related
pathologies, including retinal degeneration,8,9 retinal hypox-
ia,10–13 retinitis pigmentosa,14–16 retinal detachment,17 and
glaucoma.18,19 Retinal damage from these pathologies can be
lessened by administering the calpain inhibitor SJA6017.8,20–22
However, since the human retina expresses several calpains, it
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is not known which isoform(s) SJA6017 inhibits. Both CAPN1
and CAPN2 are expressed in the retina and show increased
activity in other neurodegenerative conditions and hypoxic
cell death.8,20 CAPN10 and calpastatin also are expressed in
the retina23,24 and CAPN3 expresses a retina-specific splice
variant in rats.8,25 Although CAPN3 is linked to limb-girdle
muscular dystrophy type 2A,26 it is not associated with any
known retinal disease. CAPN5, the most distant calpain family
ortholog,7 is the only retinal calpain known directly to trigger
retinal disease in humans. Inhibition of CAPN5 might be
therapeutic, but a specific inhibitor has never been isolated;
and sequence analysis shows CAPN5 does not bind calpastatin,
the endogenous calpain inhibitor.7,27
To increase our understanding of CAPN5 in the healthy
retina and during ADNIV, we characterized CAPN5 mRNA and
protein expression in the normal retina. We also drew from
rich compilations of genetic-variance expression databases and
performed antibody epitope-structure analysis, immunohisto-
chemistry, and subcellular fractionation.
METHODS
Human ADNIV Electroretinogram (ERG)
The collection of data used in this study was approved by the
Institutional Review Board for Human Subjects Research at the
University of Iowa, was compliant with the Health Insurance
Portability and Accountability Act, and adhered to the tenets of
the Declaration of Helsinki. A full-field ERG was performed
according to international standards. Briefly, the eyes were
dilated and dark adapted for 30 minutes. Electroretinograms
were recorded simultaneously from both eyes using Burian-
Allen bipolar contact lens electrodes as described previously.28
Evoked waveforms, a 100 lV calibration pulse, and a stimulus
artifact were recorded on Polaroid film.
RNA Preparation and Next-Generation Sequencing
The Institutional Animal Care and Use Committee (IACUC)
approved all experiments. Rodents were used in accordance
with the ARVO Statement for the Use of Animals in Ophthalmic
and Vision Research, as well as the Policy for the Use of
Animals in Neuroscience Research of the Society for Neuro-
science. Total RNA was extracted from mouse retinas and cell
lines using RNAeasy (Qiagen, Hilden, Germany), and submitted
to Otogenetics Corporation (Norcross, GA, USA) for RNA-Seq
assays. Libraries were sequenced via Illumina HiSeq2000.
Paired-end 90 or 100-nucleotide reads were generated and
checked for data quality using FASTQC (Babraham Institute,
Cambridge, UK), and analyzed using DNAnexus (DNAnexus,
Inc., Mountain View, CA, USA). Gene expression levels for
human retina were collected from GEO Omnibus (accession
number, GSE40524).
Variant Annotation and Filtering
Variants in the 1000 Genomes, Epi4k, and Autism datasets
were annotated with minor allele frequencies (MAFs) from EVS
and database of single nucleotide polymorphisms (dbSNP)
using GATK’s VariantAnnotator29 and SNPSift/SNPEff.30 Non-
coding variants, those not passing quality filtering and those
with a MAF >2% were removed. CAPN5 variants were
downloaded from the Exome Variant Server (EVS) website
(available in the public domain at http://evs.gs.washington.
edu/EVS/). Only nonsynonmous variants with an MAF <2% in
either the EA or AA populations were analyzed.
We obtained vcf files from the database of genotypes and
phenotypes (dbGAP) entry for the ARRA Autism Sequencing
Collaboration (phs000298). Only those consented for autism
research only (AO) were downloaded. The data set(s) were
deposited by the ARRA Autism Sequencing Collaborative, an
ARRA funded research initiative. Support for the Autism
Sequencing Collaborative was provided by Grants R01-
MH089208 awarded to Mark Daly, R01-MH089175 awarded
to Richard Gibbs, R01-MH089025 awarded to Joseph Bux-
baum, R01-MH089004 awarded to Gerard Schellenberg, and
R01-MH089482 awarded to James Sutcliffe.
Exome vcf files from the Epi4k Epilepsy Phenome/Genome
Project (EPGP) were requested and downloaded from dbGAP
(dbGAP Study Accession, phs000653.v2.p1). Our appreciation
goes to the Epilepsy Epi4k consortium: Discovery in Epilepsy
study (NINDS U01-NS077303) and the Epilepsy Genome/
Phenome Project (EPGP-NINDS U01-NS053998).31,32
Cell Culture, Reagents, and Antibodies
Cell lines HEK293T, SH-SY5Y, and Y79 were purchased from the
American Type Culture Collection (ATCC; Manassas, VA, USA).
Antibodies used were anti-GAPDH antibody (sc-32233), goat anti-
rabbit, and goat anti-mouse secondary antibodies (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA, USA); rabbit anti-CAPN5
polyclonal antibodies (GTX103264; GeneTex, Irvine, CA, USA;
12373-1-AP; Proteintech Group, Inc., Chicago, IL, USA; sc-50500
and sc-271271; Santa Cruz Biotechnology, Inc.) rabbit anti-myc
tag antibody (ab9106) and other anti-CAPN5 antibodies
(ab28280, ab38943, and ab97534; Abcam, Cambridge, MA, USA).
HEK293T adherent cells were grown in complete Dulbec-
co’s modified Eagle’s medium (DMEM) with 10% fetal bovine
system (FBS). SH-SY5Y adherent cells were cultured in a 1:1
mix of RPMI 1640 and F-12 media containing 10% FBS. Human
retinoblastoma Y79 cells were grown in RPMI-1640 medium
containing 20% FBS. All cultures contained penicillin (100 U/
mL) and streptomycin (100 lg/mL).
Western Blot
Levels of CAPN5 were detected by immunoblot. Cells were
lysed 24 hours after transfection, and total cellular protein
measured using NanoDrop 2000c (Thermo Fisher Scientific,
Inc., Rockford, IL, USA). Samples were electrophoretically
resolved by 4% to 12% Bis-Tris PAGE (Life Technologies; Grand
Island, NY, USA) and transferred to nitrocellulose (iBlot; Life
Technologies). Membranes were blocked with 5.0% nonfat dry
milk in 13TBS 0.1% Tween-20. Primary antibodies were diluted
1:1000; secondary antibodies 1:10,000. Immunoreactive bands
were visualized by Supersignal West Dura Extended Duration
Substrate and a MYECL Imager (Thermo Fisher Scientific, Inc.).
Subcellular Fractionation
Frozen bovine retinas were thawed and gently vortexed in
buffer A (50% sucrose, 10 mM HEPES, pH7.4, 1 mM EDTA, 5
mM MgCl2) supplemented with a protease inhibitor cocktail
(Complete; Roche, Mannheim, Germany). After 13,000g
centrifugation (1 hour), rod outer segments (ROS) were
collected and the pelleted ‘‘rest of retina’’ (ROR) resuspended
in Buffer A without sucrose. A centrifugation step (750g, 10
minutes) isolated nuclei. The ROR was centrifuged (100,000g,
1 hour) to separate soluble proteins (ROR-S1) from membranes
(ROR-P1). The ROR-P1 was loaded on a 1.2 M sucrose cushion
and centrifuged (200,000g, 30 minutes). Synaptosomes (Syn-
S2) were collected from the top of the sucrose cushion;
pelleted material was the ‘‘rest of membranes’’ fraction (ROM-
P2). Dilutions for antibodies to retinal markers were: anti-RDS
(1:30, Per 2B6, gift from Robert Molday); mouse anti-NKA
(1:1000, M7-PB-E9, Santa Cruz Biotechnology, Inc.); rabbit anti-
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HCN1 (1:2500)33; mouse anti-actin (1:1000, AC-74, Sigma-
Aldrich Corp., St. Louis, MO, USA); rabbit a-GAPDH (1:250,
Abcam); rabbit anti-RAB3 (1:500, Thermo Fisher Scientific,
Inc.); rabbit anti-VAMP2 (Synaptic Systems, Go¨ttingen, Ger-
many), mouse anti-PSD-95 (1:500, Millipore, Billerica, MA,
USA). Rat brains were collected and fractionated according to
the previously described protocol.34
Immunohistochemistry
Sections (7 lm) of fixed (4% paraformaldehyde) retina
underwent immunohistochemistry (IHC) as described.3 Images
were captured using a Zeiss LSM 710 and Zen2009 software
(Zeiss, New York, NY, USA).
Structural Modeling
The MODELLER server, ModWeb,35,36 generated a CAPN5
structural model based on the crystal structure of rat calpain-2
(3BOW). Compared to the template, the RMSD was < 0.189
over 349 Ca atoms. PyMOL generated all structure figures.
37
RESULTS
CAPN5 Gene Variants Are Only Linked to Retinal
Disease
Autosomal dominant neovascular inflammatory vitreoretinop-
athy is an extraordinarily rare disease. We reported only three
independent ADNIV pedigrees1; all harbor missense mutations
in CAPN5 exon 6, which encodes the protease core domain.
All ADNIV alleles change a single amino acid in a gating loop1,4
and seem to generate a hyperactive protease.7 We searched for
ADNIV-like mutations in normal and disease-associated geno-
mic databases to test whether other diseases that have been
linked to increased calpain activity also are caused by
hyperactive calpain mutants.
To determine the frequency of CAPN5 variants, we mined
the 1000 Genomes38,39 and EVS databases,40 which contain
DNA sequences from a healthy human population. Using
PolyPhen to estimate variant pathogenecity, our survey predict-
ed that <2% of CAPN5 gene variants are damaging alleles. This
prediction was greater than the actual prevalence of intraocular
inflammation (estimated between 17.5–111.1 per 100,000
population), consistent with the reported false-positive rate of
PolyPhen predictions. Overall, mapping showed most CAPN5
variants, especially missense and splice-site variants, exist
outside the proteolytic core (Fig. 1). The absence of variants
in the proteolytic core supports the idea that proteolytic core
mutations are particularly damaging. This is consistent with the
high penetrance, rarity, and severity of the ADNIV phenotype.
Increased calpain activity is associated with cancer,41 and
genetic studies link polycystic ovarian and rectal cancers to
CAPN5.25,42 We first searched for CAPN5 variants in the
Catalogue of Somatic Mutations in Cancer (COSMIC) Database,
which holds sequences from 1.1 million sample genomes from
43 types of cancer.43,44 Only 39 CAPN5 missense variants
occurred in the proteolytic core (and two stop codon variants),
27 of which could potentially alter CAPN5 activity (Supple-
mentary Fig. S1).1,5,8,23–25,45–49 No variants were found in the
CAPN5 gating loop and none matched the previously identified
ADNIV alleles. These results suggested CAPN5 variants are rare
in cancer, so higher calpain activity in cancer cells is not due to
hyperactivating CAPN5 mutations.
CAPN5 is highly expressed in the brain,50 and increased
calpain activity has been associated with epilepsy.51–57 To
determine if rare CAPN5 coding variants could be contributing
to the incidence of neurodevelopmental disorders, we queried
an epilepsy and autism dataset for mutations in CAPN5 and
compared the variant counts in each cohort to EVS and 1000
genomes. No significant enrichment was found in either the
epilepsy or autism cohorts. Again, this suggests the increased
calpain activity associated with epilepsy is not due to hyper-
activating CAPN5 mutations.
CAPN5 mRNA Is Widely Expressed
Prior Northern analysis on adult mouse mRNA showed that
CAPN5 mRNA was widely expressed, particularly in the brain,
eye, uterus, lung, submaxillary gland, prostate, and epididy-
mis.6 To further evaluate tissue-specific CAPN5 expression, we
used two recent online expression databases (Summarized in
the Table). Biogps, which tracked mRNA levels in 79 human
and 61 mouse tissues,58,59 showed that CAPN5 expression is
highest in human colon, heart, liver, prostate, and skeletal
muscle. Human retinal tissue expressed CAPN5 at levels
slightly above average. Mice expressed CAPN5 highest in the
uterus and digestive system, with only low to moderate
expression in the eye. The EMBL-EBI gene expression database
reported CAPN5 expression in eight humans and 12 mice,60
and confirmed high expression in the human digestive system.
In contrast to the Biogps, however, these studies found
significant expression of CAPN5 in mouse brain tissue. This
dataset did not track CAPN5 expression in eyes.
FIGURE 1. CAPN5 EVS Variants. Public exome databases show common variants in CAPN5 by amino acid position and type. The CAPN5 gene is 59
kilobases, contains 13 exons, and generates a 2791 nucleotide transcript (encompassing all purported isoforms) that encodes a 640 amino acid
protein. Shown here, this data set serves as a normative database for CAPN5 variants, and depicts the relationship of these variants to functional
residues and domains within CAPN5. Variants are rare within the proteolytic core, where retinal disease alleles are located. The EVS sequenced over
6476 individuals, with high CAPN5 coverage, and found no frameshift variants, two premature stop-codon variants, 843 missense variants (of which
237 were splice-site mutations), and 681 synonymous variants. Of these variants, the majority was scored as either ‘‘unknown’’ or ‘‘benign’’ by
PolyPhen. PolyPhen predicted that 1% and 0.83% of the population has ‘‘Possibly Damaging’’ and ‘‘Probably Damaging’’ alleles, respectively.
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The Retina Expresses Several But Not All Calpain
Family Members
We applied RNA sequencing to compare expression of CAPN5
mRNA to that of other calpains in the mouse retina (Fig. 2).
Among the 10 calpain genes (CAPN1, 2, 3, 5, 6, 7, 10, 12,
CAPNS1, and CAST), CAPN5, 7, 10, 2, and CAPN1S1 were the
most highly expressed (Fig. 2A). Interestingly, except for CAPN2,
these variants do not contain an EF-hand domain (a calcium
binding, helix-turn-helix motif) believed to mediate protein-
protein interactions of the most abundant calpains.61 The mouse
retina expressed only the full-length CAPN5 transcript, as we
reported in humans.1,3 Expression of CAPN5 measured a mean
of 0.003259 RKPM, approximately half that of the most abundant
calpains, CAPN2 and CAPN7 (Fig. 2A). The relative expression
level of CAPN5 RNA was four orders of magnitude less than that
of the highly expressed phototransduction genes (Fig. 2). Our
transgenic mouse model of ADNIV shows a less severe
inflammatory phenotype than humans,5 but here we found that
the calpain family mRNA expression pattern in mouse and
human retina was similar (Fig. 2B). There were only minor
differences between human and mouse. CAPN1, CAPNS2, and
CAST were higher in human retina (Figs. 2B, 2C).
The human retinoblastoma Y79 cell line offers an in vitro
model of photoreceptors. In these cells, CAPN5 was expressed
at significantly lower levels (5.580e-005 6 8.391e-005);
otherwise, the pattern matched the human and mouse retinas
where CAPN2 and CAPN7 were the most expressed calpains
(Fig. 2C).
Calpains mediate inflammatory necrotic cell death and
frequently are compared to caspases, which mediate apopto-
sis.62,63 Eight members of the caspase family were expressed in
the retina at levels similar to calpains, which suggests the retina
is not biased towards a specific cell-death pathway.
CAPN5 Protein Is Widely Expressed
The Human Protein Atlas describes protein expression across
80 major tissues and organs using antibody-based methods and
transcriptomics (summarized in the Table).64,65 CAPN5 protein
was detected in 22 distinct normal tissues, mirroring data from
the mRNA expression databases. Notably, the Human Protein
Atlas data also described equivalently strong expression of
CAPN5 in the kidney, bladder, testes, prostate, skin, lungs, and
endocrine organs, and moderate expression throughout the
digestive tract. CAPN5 also was detected in several brain
regions (i.e., cerebral cortex, hippocampus, lateral ventricle,
and cerebellum). CAPN5 protein was detected in the
cytoplasm, nucleolus, and cell membrane. Limitations of this
dataset were the lack of eye tissues and use of only one CAPN5
antibody.
CAPN5 Detection in Neuronal Cells Varies by
Antibody
Seven commercial CAPN5 antibodies were tested in Western
blots of HEK-293T cells expressing recombinant CAPN5 cDNA.
Antibodies had been generated against different CAPN5
regions (Fig. 3B). Antibodies Ab-2, -6, and -7 showed distinct
CAPN5 immunoreactive bands. The strongest signal with the
least background was detected by Ab-7, which was generated
against CAPN5 domains I, II, and the first 38 amino acids of
domain III (Fig. 3C). This antibody did not crossreact with
other calpain family members (data not shown). The remaining
antibodies detected CAPN5, but gave high background and
nonspecific bands (data not shown). Interestingly, two neural
cancer lines, SHSY5Y neuroblastoma and Y79 retinoblastoma
cells, express endogenous CAPN5 and showed lower molec-
ular weight species not present in transfected HEK-293T cells
(Fig. 3D). Since self-cleavage is a known feature of other
calpains,61 and calpain autoproteolysis releases a catalytic
protease core, the approximately 50 kDa species detected in
SHSY5Y and Y79 cells could represent the protease core
(domain II) of autoproteolyzed CAPN5. This suggests CAPN5
may undergo a basal level of cell-line specific autoproteolysis,
which could impact expression studies.
In Western blots of extracts from mouse and human retina,
Ab-7 detected endogenous CAPN5 species that appeared to be
the full-length protein1,5 (Fig. 3E); the retinal extracts did not
contain low molecular weight species like those found in
cancer cells, suggesting calpain autoproteolytic activity is not a
feature of the normal healthy retina. Interestingly, Ab-7 also
recognized Tra-3, the distant Caenorhabditis elegans paralog
of CAPN5 (Fig. 3E) despite that an alignment of Tra-3 with
human CAPN5 showed less than 40% identity (Fig. 4A).
Together, these findings suggest that for optimal Western
analysis of CAPN5, the best antibodies were polyclonal and
likely targeted conformational epitopes in all four domains.66
To test this, a custom antibody was generated using a
polypeptide comprised of sequences from all four human
CAPN5 domains that were homologous to Tra-3, distinct from
other retinal calpain family members, and predicted to be on
the CAPN5 surface (according to our published structural
model: Figs. 4B, 4C and Supplementary Fig. S2).4,5 This
recombinant antigen was expressed in Escherichia coli,
purified, and injected into rabbits to yield polyclonal Ab-8
(Supplementary Fig. S2). Antibody Ab-8 detected CAPN5 via
Western blot at levels comparable to Ab-7 (Fig. 4D). Overall,
these results suggest CAPN5 antibodies raised against different
regions also might show differences in vivo, an important
consideration when interpreting CAPN5 expression.
CAPN5 Is Expressed in Several Regions of the
Mouse Retina
The retina contains several cell types in layers of highly
organized circuits. Previously, we reported CAPN5 was
expressed in the inner and outer segments (IS and OS,
TABLE. Gene and Protein Expression of Calpain Family Members in
the Retina
Gene Calpain mRNA in Retina
Calpain Protein in
Retina
CAPN1 Human,* mouse,* rat49 Rat,23,45 pig,23,45 human,8
monkey,8 rabbit8
CAPN2 Human,* mouse,* rat49 Rat,23,45 pig,23,45 human,8
monkey,8 rabbit,8 cow46
CAPN3 Splice variants rat,47
human,25 monkey25
Splice variants rat47
CAPN5 Human5, mouse* Human,1 mouse5
CAPN6 Human,* mouse* N/A
CAPN7 Human,* mouse* N/A
CAPN8 – N/A
CAPN9 Human,* mouse* N/A
CAPN10 Splice variants human,48
mouse,24 rat49
Splice variants rat,24
mouse,24 human24
CAPN11 Human,* mouse* N/A
CAPN12 Human,* mouse* N/A
CAPN13 N/A N/A
CAPN14 N/A N/A
CAPN15 N/A N/A
CAPN16 N/A N/A
N/A, not applicable.
* Current study.
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respectively) of human and mouse photoreceptors using Ab-
2.1,5 Probing the mouse retina with Ab-4, however, revealed
that CAPN5 also was modestly expressed in the outer
plexiform layer (OPL).5 With these disparities, we used the
newly characterized Ab-7. This labeled the photoreceptor
inner segments as well as the OPL, where photoreceptors form
synaptic connections with bipolar cells and others in the inner
nuclear layer (INL; Fig. 5). CAPN5 colocalized with PSD-95, a
protein expressed specifically in photoreceptor synapses,
where a signaling defect could correlate with the electroneg-
ative ERG found in ADNIV patients (Fig. 5). Additionally
CAPN5 was detected at a lower level in some, but not all retinal
ganglion cells (RGC). Lower levels of CAPN5 were detected in
the INL and inner plexiform layer (IPL; Fig. 5). Finding CAPN5
localized to these sites suggests a role in synaptic transmission.
CAPN5 Localizes to Photoreceptor Synapses
To explore CAPN5 subcellular localization, retinal extracts
were fractionated and analyzed by Western blot (Fig. 6). Rod
outer segments were first isolated by sucrose flotation. CAPN5
was detected in the crude ROS fraction. The remaining retinal
proteins (ROR) were separated into soluble (ROR-S1) and
membrane (ROR-P1) fractions. CAPN5 was detected largely in
FIGURE 2. RNA sequence analysis of human and mouse retina. (A) Calpain expression in the mouse retina, as compared to levels of caspase
expression, phototransduction genes, and housekeeping genes as controls (n¼3). Results show CAPN5 expression is approximately half that of the
most abundant calpains, CAPN2 and CAPN7. Calpain expression is comparable to caspase expression in the mouse retina. Expression of CAPN5 is
several orders of magnitude less than phototransduction genes and control genes. (B) Slightly different patterns of expression are seen in the human
retina (n¼3). (C) Calpain expression observed in Y79 cells as compared to levels of caspase expression, phototransduction genes, and controls (n¼
3). Similar to human and mouse retina, CAPN2 and CAPN7 are the most abundant calpains in Y79 cells, but CAPN5 expression is lower.
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FIGURE 3. CAPN5 Western blot shows specificity of multiple CAPN5 antibodies. (A) Schematic diagram of human CAPN5 protein domain structure. CAPN5
is composed of 640 amino acids that comprise four domains (A). Domain-I spans amino acid residues 1 to 25. Domain-II is the protease core and spans amino
acid residues 26 to 343; it consists of two subdomains that together contain the catalytic triad and calcium binding sites. Domain II also contains the three
different ADNIV-causing mutations.3 Domain-III spans amino acid residues 344 to 496 and contains a calcium-binding site leading to speculation that it is a
regulatory region. Domain-IV (C2) also is believed to be regulatory; it spans amino acid residues 518 to 619, and contains three calcium-binding sites. (B) A
diagram showing the epitopes of the seven different commercially available anti-CAPN5 antibodies tested, as well as the companies they were obtained from.
Antibody Ab-1 (ab28280) mainly targeted domain I; Ab-2 (sc-50500) and Ab-3 (sc271271) targeted all of domain I, and part of domain II (catalytic domain); Ab-
4 (ab38943) targeted the entire domain II and part of domain III; Ab-5 (12373-1-AP) and Ab-6 (ab97534) targeted domains I, II, and part of III. All antibodies
were rabbit polyclonal antibodies, except for Ab-3, which was a mouse monoclonal antibody. (C) Immunoblots of HEK-293 cells transfected with full-length
CAPN5 (tagged with c-myc and flag tag) and probed separately with three unique anti-CAPN5 antibodies. Anti-GAPDH antibody was used as a protein loading
control. Immunoglobulin G (IgG) was used as a negative control. The closed arrows indicate CAPN5 bands at approximately 75 kDa, while the open
arrowheads indicate GAPDH bands at approximately 37 kDa. Immunoblot images were captured with an ECL imager. Antibody Ab-7 consistently gave the
best bands with the least amount of background, indicating higher specificity for CAPN5. (D) Immunoblots of HEK-293, SY-SH5Y, and Y79 cells transfected
with full length CAPN5 and probed with Ab-4. (E) Immunoblots of retinas belonging to human and mice were probed separately with CAPN5 specific Ab-7.
Immunoblot of protein obtained from wildtype (N2) C. elegans. 10 lg of protein were loaded.
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FIGURE 4. Customized antigen raises highly specific CAPN5 antibodies. (A) Alignment of CAPN5 and Tra-3 sequences. Regions of homology are shown in
black. Regions corresponding to the customized CAPN5 antigen are underlined with colors corresponding to the different CAPN5 domains. (B) A structural
model of CAPN5. The highlighted regions correspond to those recognized by our custom antibody. (C) A diagram showing the epitopes of our custom anti-
CAPN5 antibody. (D) Immunoblots of HEK-293 cells transfected with full-lengthCAPN5 and probed with our custom anti-CAPN5 antibody. We used GAPDH
as a protein loading control. Preimmune-serum obtained from the same animal was used as a negative control. The closed arrows indicate CAPN5 bands at
approximately 75 kDa, while theopenarrowheads indicate GAPDH bands at approximately 37 kDa. Immunoblot images were captured with an ECL imager.
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the soluble pool (Fig. 6). Interestingly, CAPN5 also was
detected in the membrane fraction that is enriched for
synaptosomes (Syn-Soluble, Fig. 6). This analysis was consis-
tent with immunohistochemical localization of CAPN5 to
photoreceptor synapses. Expression at these synapses explains
a defining feature of ADNIV, loss of the electroretinogram b-
wave (see Discussion).
Subcellular Localization of CAPN5 in the Rat Brain
The compartmentalization of CAPN5 in the retina suggests that
CAPN5 function might be regulated by subcellular localization.
To examine localization further, we used rodent brain cells as a
source of material, since the brain expresses more CAPN5 than
the retina, and brain tissue is far more abundant.50 Brain extracts
were fractionated and probed with CAPN5 Ab-1, -2, and -7. In
parallel, fractions also were probed with a panel of antibodies
that marked various subcellular compartments (Fig. 7).
As seen in cultured neural cells, the brain expressed
multiple species of CAPN5 immunoreactivity, potentially
reflecting autoproteolysis. Comparing expression patterns on
Western blots, as detected by Ab-1, -2, and -7 (all polyclonal),
we noticed each antibody gave a distinct pattern. Antibody Ab-
1, which targets the 30 N-terminal amino acids, primarily
recognized the smaller, more processed forms of CAPN5.
Antibody Ab-2, which targets Domain I and part of Domain II,
appeared to recognize both full-length and proteolytically
processed forms, but the electrophoretic mobility of the high
molecular weight forms were the same as those detected by
Ab-1. Antibody Ab-7, which targets full-length CAPN5, recog-
nized few approximately 50 kD species, preferring the full-
length form. Thus, the presence of smaller species could
indicate cellular compartments with greater CAPN5 proteolytic
activity or the accumulation of the autoproteolyzed CAPN5
proteolytic core (~50 kD).
The patterns on Western blots suggest the different
antibodies preferentially recognized different forms of CAPN5.
The banding patterns indicates Ab-2 recognized the full-length
and proteolytically processed forms of CAPN5, while Ab-1 and
Ab-7 preferentially recognized the processed and full-length
forms, respectively. The blots show the 50 kD form was
enriched for in a crude synaptosomal/mitochondrial fraction
(syn-mt).67,68 The link between CAPN5 and the synapse and
mitochondria has interesting implications, since mitochondria
are highly enriched in the synapse due to energy needs
associated with neurotransmitter loading and release.69 More-
over, synapses and mitochondria are rich in calcium stores,
which might activate CAPN5 and trigger autoproteolysis.
DISCUSSION
The calpains are calcium-dependent, intracellular, cysteine
proteases70,71 that proteolytically process targets into new
functional forms. Calpains are regulatory proteases and have
been linked to a broad spectrum of cellular processes,
including cell death, cell movement, sex determination, and
intracellular signaling.14,15 Excess, uncontrolled calpain
activity is implicated in cancer pathogenesis,72 muscular
dystrophy,73 diabetes,74 and a number of neurologic diseases,
such as multiple sclerosis,75 Alzheimer’s disease,76,77 Hun-
tington’s disease,78 and traumatic brain injury.71,79 Compared
to the rest of the calpain family, CAPN5 is especially
interesting because it is the only known calpain with a
human disease mutation that renders the protease intrinsical-
ly hyperactive.
Autosomal dominant neovascular inflammatory vitreoreti-
nopathy phenotypically overlaps with several other eye diseases.
For example, electronegative ERGs also are observed in
retinoschisis, quinine toxicity, and congenital stationary night
blindness (CSNB). Interestingly, CSNB and retinal degeneration
in the rd1 mouse are associated with excess calpain activity.80
Additionally, the proliferative retinal neovascularization in
ADNIV patients has been confused with diabetic retinopathy,
but ADNIV patients are not diabetic and do not show retinal
capillary nonperfusion or other signs of retinal or ocular
ischemia. Instead, the proliferative changes are likely driven by
uveitic inflammatory signals. It is interesting to speculate that
calpains might be active in shared downstream pathways.
The expression of CAPN5 varies in abundance and in the
appearance of proteolytically processed forms. Since our
custom polyclonal CAPN5 antibody was raised to domains
unique to CAPN5 that represented surface epitopes across the
entire protein, it would be expected to recognize all forms of
CAPN5 and all fragments that might be generated by
autoproteolysis. Indeed, when interpreting immunohistochem-
ical studies of calpains and their proteolytic targets, it is
important to note that the various proteolyzed (or autoproteo-
FIGURE 5. CAPN5 Immunohistochemistry in the retina synapse. (A) CAPN5 expression was present along a region corresponding to the OPL of the
retina, where photoreceptors form synaptic connections with bipolar cells. PSD95 expression, a marker of neural postsynaptic densities,
colocalized with CAPN5 expression along the synapses forming the outer plexiform layer. (B) The retinal synaptic circuit begins with light
depolarization (a-wave) at the photoreceptor. Synaptic transmission from the photoreceptor to the bipolar cell and then to the RGC generates the
hyperpolarized b-wave. This is shown in human ERG that trace the a- and b-waves in an ADNIV patient and a wildtype individual. Early in ADNIV
patients and transgenic mouse models, the a-wave is intact but the b-wave is reduced (electronegative), indicating a defect in synaptic signaling
between the photoreceptor and bipolar cell. The unusual phenotype is explained by CAPN5 localization to this synaptic junction. Scale bar: 10 lm.
Blue¼ DAPI; Red¼ PSD95; green¼ CAPN5.
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lyzed) forms would be expected to have different surface
epitopes. The different patterns seen with different antibodies
might reflect unique autoproteolytic domains of CAPN5, like
that seen in the subcellular fractionation experiments.
In the retina, an examination by IHC using different
antibodies revealed patterns of CAPN5 subcellular localization.
In photoreceptors, for example, CAPN5 is in the outer
segment,1,5 where light is converted into cellular signals; the
nucleus, where transcription takes place; and the synapse,
which transmits signals to the inner retina. Newly available
antibodies revealed expression in the inner nuclear layer and
ganglion cell layer. In ADNIV patients, however, neither the
RGCs nor the optic nerve degenerate. Instead, similar to
patients with retinitis pigmentosa, ADNIV patients lose
peripheral vision coincident with degeneration of their
peripheral photoreceptors. Nevertheless, electrophysiologic
testing of the optic nerve with pattern ERG (PERG), for
example, may be worthwhile, since PERG can assess macular
ganglion cell function. In addition, future immunohistochem-
istry studies using RGC markers might identify the subtypes of
RGC cells expressing CAPN5.
Calpain proteolysis is linked with synaptic function.81 Since
the known calpain substrates include cytoskeletal proteins,
membrane receptors, and postsynaptic-density proteins, calpain
proteolysis of these substrates might be a feature of normal
synaptic function.81 Pharmacologic inhibition shows calpains
have key roles in many neuronal processes including neuro-
transmitter release and signal transduction.81 The high expres-
sion of CAPN5 we observed in the photoreceptor synaptic layer
(OPL) and mitochondria supports a role for CAPN5 at synapses.
This is interesting because it may explain the development of
early ADNIV electronegative ERG where loss of the b-wave is a
sign of defective inner retina neurotransmission.
The genomic survey was designed to help uncover why ADNIV
CAPN5 alleles cause retinal disease, and whether such alleles cause
other diseases linked to high calpain activity. Our PolyPhen
predictions of CAPN5 variants in genome databases suggest
damaging alleles arise at a very low frequency, implying they are
highly detrimental. More specifically, we found very few protease-
core variants, which are likely to be more damaging than variants in
the N-terminal or C-terminal regions. Increased calpain activity has
been associated with cancer and epilepsy, but we found few
CAPN5mutations, suggesting that in those diseases calpain activity
is elevated for reasons other than calpain mutations while the
current CAPN5 variants only display retinal disease.
FIGURE 6. CAPN5 co-fractionates with both soluble and synaptic vesicle proteins. (A) A schematic illustration of a photoreceptor cell maps the
location of subcellular marker proteins. (B) Antibodies against CAPN5 were used to probe retinal protein fractions alongside protein markers for
specific retinal compartments. CAPN5 was detected in the ROS, but most of it remained in the ROR fraction. After the ROR was fractionated to
enrich for soluble (ROR-S1), membrane (ROR-P1), and synaptic (Syn-S2) proteins, CAPN5 was found in the soluble and synaptic vesicle pools (along
with Actin and GAPDH, or RAB3 and VAMP2, respectively). NKA, sodium potassium ATPase; HCN1, hyperpolarization-activated and cyclic
nucleotide-gated channel, family member 1.
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Even though we found calpain mRNA expression patterns
were similar between mouse and humans, our previously
reported ADNIV mice3 had a less severe form of the disease;
this may happen for several reasons. For example, in one
mouse model CAPN5 was expressed from a retroviral vector,
which gave a transient and patchy expression pattern in the
host retina.3 In a second, transgenic mouse model, the ADNIV
phenotype might be ameliorated by the presence of two wild-
type alleles.5 In both models, expression is restricted to
photoreceptors and not other retinal cells where CAPN5 is
natively expressed. It also is possible that the short mouse
lifespan ends before the disease can develop into full-blown
ADNIV, since humans do not typically display severe disease
until their fourth decade or later. To distinguish the possibilities
from species differences, we will have to generate knock-in
mice that replace the normal alleles with disease alleles under
the native promoter.
Although ADNIV only affects the eye, CAPN5 mRNA was
expressed at only slightly above average levels in the retina and
at far higher levels in the colon. Nevertheless, to date no
ADNIV patients have gastrointestinal disorders. These data
support the idea that CAPN5 is uniquely regulated and/or
serving a highly specialized role in the retina. For example,
ADNIV CAPN5 mutations might specifically cause a retinal
phenotype because photoreceptors use extremely high calci-
um levels for phototransduction. High calcium could not only
activate CAPN5 transiently, but render it permanently hyper-
active by autoproteolytically cleaving out an active fragment
that is free of regulatory domains.1 Alternatively, in the eye, the
uniquely slow turnover rate of cells might allow retinal damage
to accumulate and become more severe than in a tissue with a
faster turnover rate (e.g., the digestive tract). Regardless of the
mechanism that restricts the clinical disease to eye tissue, the
subcelluar localization of CAPN5 indicates it likely targets
several different proteins with nonoverlapping functions. This
would account for the complex ocular phenotype. Thus, the
next important step for understanding ADNIV and devising
new therapies will be to identify the proteolytic targets of
CAPN5.
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